(VIANEWS) – Another day of trading has ended and here's today's list of stocks that have had significant trading activity in the US session.

The three most active and biggest winners today are iFresh, CommScope Holding Company, and DMC Global.

The three most active and biggest losers today are China Auto Logistics, Wayfair, and Clovis Oncology.

Most Active Winners today

1. iFresh (IFMK) – 115.38%

Through its subsidiaries, iFresh Inc. operates a network grocery store chains in the northern-eastern United States. The company operates in two segments: Wholesale and Retail. It offers vegetables, seafood and meats as well as snacks and seasonings. The company's brands include Feiyan and Green Acre as well as Redolent and Redolent. It also sells products in wholesale shops, supermarkets and restaurants. It had nine supermarkets, two wholesale shops and one in-house business. It sells its products online and has a delivery network throughout suburban areas. Founded in 1995, iFresh Inc. is headquartered on Long Island City in New York.

NASDAQ ended the session with iFresh jumping 115.38% to $0.01 on Thursday while NASDAQ fell 4.99% to $12,317.69.

Volume

Today's last reported volume for iFresh is 311 which is 90.9% below its average volume of 3419.

iFresh's last close was $0.01, 99.7% under its 52-week high of $1.68.

iFresh's Revenue

Year-on-year quarterly revenue growth grew by 22.7%, now sitting on 94.26M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

iFresh's stock is considered to be overbought (>=80).

iFresh's Stock Yearly Top and Bottom Value

iFresh's stock is valued at $0.01 at 17:32 EST, way below its 52-week high of $1.68 and way above its 52-week low of $0.00.

iFresh's Moving Average

iFresh's value is way below its 50-day moving average of $0.01 and way under its 200-day moving average of $0.50.

More news about iFresh.

2. CommScope Holding Company (COMM) – 12.23%

CommScope Holding Company, Inc. offers infrastructure solutions to communications and entertainment networks. The company operates in four segments, Broadband Networks, Home Networks, Outdoor Wireless Networks, Venue and Campus Networks, and Video Systems, Access Technologies, Fiber and Coaxial Cables, Copper Connectivity Products, and Hardened Closures for the cable and telco market. Subscriber-based solutions for broadband and video are offered by the Home segment. These include devices that offer residential connectivity to a service providers network such as digital subscriber lines, cable modems and telephony. They also provide Wi-Fi and routing functionality. Set-top boxes support satellite and cable TV content delivery. This includes digital video recorders and high-definition set-top box, hybrid, and fixed-base devices. OWN provides base station antennas and RF filters as well as tower connectivity and microwave antennas. It also offers cabinets, steel and accessories. Spectrum access system and Comsearch products for the metro and macro cell markets. Products from the VCN segment include Wi-Fi, switching, distributed antenna system, license and unlicensed small cell, enterprise fiber and copper infrastructures to campuses, venues and data centers. The company serves customers in Canada, America, Europe, Asia Pacific, Africa, Latin America and the Middle East. Cedar I Holding Company, Inc. was the company's former name. In January 2011, CommScope Holding Company, Inc. became CommScope Holding Company, Inc. CommScope Holding Company, Inc. is a North Carolina-based company that was established in 1976.

NASDAQ ended the session with CommScope Holding Company jumping 12.23% to $7.34 on Thursday while NASDAQ fell 4.99% to $12,317.69.

Volume

Today's last reported volume for CommScope Holding Company is 4553440 which is 1.93% below its average volume of 4643490.

CommScope Holding Company's last close was $6.54, 70.51% under its 52-week high of $22.18.

The company's growth estimates for the ongoing quarter and the next is a negative 41.7% and a negative 20.9%, respectively.

CommScope Holding Company's Revenue

Year-on-year quarterly revenue growth grew by 4.3%, now sitting on 8.59B for the twelve trailing months.

CommScope Holding Company's Stock Yearly Top and Bottom Value

CommScope Holding Company's stock is valued at $7.34 at 17:32 EST, way below its 52-week high of $22.18 and way higher than its 52-week low of $5.94.

CommScope Holding Company's Moving Average

CommScope Holding Company's worth is under its 50-day moving average of $7.54 and way under its 200-day moving average of $11.23.

More news about CommScope Holding Company.

3. DMC Global (BOOM) – 11.36%

DMC Global Inc. offers a range of products and services for global markets in the infrastructure, energy, and industrial sectors. It operates two divisions, DynaEnergetics and NobelClad. The company's NobelClad division produces and markets explosion-welded, clad metal plates that are used in construction of high temperature, corrosion resistant pressure vessels and heat exchangers. These can be used for hydrometallurgy and aluminum production as well as shipbuilding and power generation. It sells products via direct sales, program managers and independent sales reps. The company's DynaEnergetics division designs, produces, markets and sells perforating system, which includes shaped charges and detonating cords. It also manufactures gun hardware and control panels, as well as hardware and accessories for the oil-and gas industry. The company sells products via distributors and independent sales reps. The company used to be called Dynamic Materials Corp., but changed its name in November 2016 to DMC Global Inc. DMC Global Inc. was established in 1965. It is located in Broomfield Colorado.

NASDAQ ended the session with DMC Global rising 11.36% to $22.45 on Thursday while NASDAQ slid 4.99% to $12,317.69.

Volume

Today's last reported volume for DMC Global is 171197 which is 9.96% above its average volume of 155680.

DMC Global's last close was $22.45, 64.65% below its 52-week high of $63.50.

DMC Global's Sales

DMC Global's sales growth is 23.6% for the current quarter and 30.4% for the next. The company's growth estimates for the ongoing quarter and the next is 140% and 566.7%, respectively.

DMC Global's Revenue

Year-on-year quarterly revenue growth grew by 21.5%, now sitting on 245.38M for the twelve trailing months.

DMC Global's Stock Yearly Top and Bottom Value

DMC Global's stock is valued at $22.45 at 17:32 EST, way below its 52-week high of $63.50 and way higher than its 52-week low of $18.74.

DMC Global's Moving Average

DMC Global's value is way under its 50-day moving average of $29.09 and way below its 200-day moving average of $37.45.

More news about DMC Global.

4. EPAM Systems (EPAM) – 10.92%

EPAM Systems, Inc. offers digital platform engineering services and software development in North America, Europe, Armenia, Belarus, Kazakhstan, Russia, Ukraine, Asia, as well as Australia. It offers services such as platform selection and customization, cross-platform migrating, integration, and implementation; infrastructure management services like software development and testing with private and public infrastructures. These include maintenance of application, database and server storage systems, monitoring and notification services. The company also offers operation solutions, which include integrated engineering and smart automation. It provides consulting and services for customers to improve their software testing practices and to ensure that information is not lost. The company also offers technical advice, industry experience and consulting services. It also provides digital and service design services that include strategy, design and creative services as well as product development. The company serves many industries, including financial, consumer and software, hi-tech and business information, healthcare and life sciences, as well as other sectors such like travel and tourism. Curogram has partnered with EPAM Systems, Inc. to assist healthcare providers in implementing a COVID-19-simplified crisis response plan. Newtown, Pennsylvania is the headquarters of this company. It was established in 1993.

NYSE ended the session with EPAM Systems rising 10.92% to $346.75 on Thursday while NYSE dropped 2.9% to $15,652.61.

Volume

Today's last reported volume for EPAM Systems is 2490890 which is 69.04% above its average volume of 1473480.

EPAM Systems's last close was $200.14, 72.41% below its 52-week high of $725.40.

EPAM Systems's Sales

EPAM Systems's sales growth is 49.9% for the ongoing quarter and 40.3% for the next. The company's growth estimates for the present quarter and the next is 38.1% and 39.2%, respectively.

EPAM Systems's Revenue

Year-on-year quarterly revenue growth grew by 51.6%, now sitting on 3.37B for the twelve trailing months.

EPAM Systems's Stock Yearly Top and Bottom Value

EPAM Systems's stock is valued at $346.75 at 17:32 EST, way under its 52-week high of $725.40 and way above its 52-week low of $168.59.

EPAM Systems's Moving Average

EPAM Systems's worth is way higher than its 50-day moving average of $283.17 and way below its 200-day moving average of $518.13.

More news about EPAM Systems.

5. bluebird bio (BLUE) – 9.65%

bluebird bio, Inc. is a biotechnology firm that develops, markets, and sells gene therapies to treat severe genetic disorders and cancer. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent AY-thalassemia; LentiGlobin for the treatment of sickle cell disease; and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. Idecabtagene Vicleucel, and bb21217 are the company's oncology product candidates. These products can be used to treat multiple myeloma by using chimeric antigen receptor (CAR) T cell product candidates. There are license and collaboration agreements with Bristol-Myers Squibb, Regeneron Pharmaceuticals, Inc., Novartis Pharma AG, Orchard Therapeutics Limited, Medigene AG, Novo Nordisk A/S, Forty Seven, Inc., Gritstone oncology, Inc., Magenta Therapeutics, Inc., University of North Carolina, Fred Hutchinson Cancer Research Center, as well as Bristol-Myers Squibb. bluebird bio, Inc. is a member of a strategic alliance with National Resilience, Inc. for the development, delivery, and research in cell therapies. Bluebird bio, Inc., formerly Genetix Pharmaceuticals, Inc., changed its name in September 2010 to bluebird bio, Inc.

NASDAQ ended the session with bluebird bio jumping 9.65% to $4.43 on Thursday, after three successive sessions in a row of gains. NASDAQ slid 4.99% to $12,317.69, after three consecutive sessions in a row of gains, on what was a very down trend exchanging session today.

Volume

Today's last reported volume for bluebird bio is 2661380 which is 17.98% above its average volume of 2255700.

bluebird bio's last close was $4.43, 80.78% below its 52-week high of $23.05.

bluebird bio's Sales

bluebird bio's sales growth is a negative 94.3% for the ongoing quarter and a decline by 89.8% for the next. The company's growth estimates for the current quarter and the next is 54.7% and 63.7%, respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

bluebird bio's stock is considered to be oversold (<=20).

bluebird bio's Stock Yearly Top and Bottom Value

bluebird bio's stock is valued at $4.43 at 17:32 EST, way under its 52-week high of $23.05 and way higher than its 52-week low of $3.46.

bluebird bio's Moving Average

bluebird bio's value is below its 50-day moving average of $4.76 and way under its 200-day moving average of $9.73.

More news about bluebird bio.

6. argenx SE (ARGX) – 9.38%

Argenx SE is a biotechnology company in clinical stage. It focuses its efforts on the development of antibody-based treatments for autoimmune diseases and cancer. The company is currently developing efgartigimod as a lead product candidate for patients suffering from myasthenia Gravis, immune thrombocytopenia, and pemphigus vulgaris. It also has Phase 2 clinical trials in the treatment of chronic inflammatory demyelinating neuropathy. ENHANZE SC are in preclinical stages. Cusatuzumab is being developed in the Phase 2 clinical stages in hematological carcinoma indications. Preclinical products include ARGX-117, which has therapeutic potential for both large autoimmune inflammatory and orphan diseases. ARGX-118 treats airway inflammation. ARGX-112 to treat skin inflammation, and ARGX115 for cancer immunotherapy are its partnered products. These are currently in Phase 1 clinical phases. ARGX116 is for treatment dyslipidemia, and ARGX114 for treating fibrosis. AbbVie S.AEUR.R.L. is the company's strategic partner. LEO Pharma A/S, Cilag GmbH International, Staten Biotechnology B.V. and Shire International GmbH. argenx SE was established in 2008, and it is located in Breda in the Netherlands.

NASDAQ ended the session with argenx SE jumping 9.38% to $320.40 on Thursday, following the last session's downward trend. NASDAQ dropped 4.99% to $12,317.69, after three successive sessions in a row of gains, on what was a very bearish trend trading session today.

Volume

Today's last reported volume for argenx SE is 968036 which is 289.61% above its average volume of 248462.

argenx SE's last close was $278.23, 22.02% below its 52-week high of $356.78.

argenx SE's Sales

argenx SE's sales growth is a negative 39.5% for the current quarter and a decline by 91% for the next. The company's growth estimates for the current quarter and the next is a negative 12.8% and a negative 481.5%, respectively.

argenx SE's Revenue

Year-on-year quarterly revenue growth declined by 46.5%, now sitting on 510.08M for the twelve trailing months.

argenx SE's Stock Yearly Top and Bottom Value

argenx SE's stock is valued at $320.40 at 17:32 EST, way under its 52-week high of $356.78 and way higher than its 52-week low of $248.21.

argenx SE's Moving Average

argenx SE's value is above its 50-day moving average of $300.99 and higher than its 200-day moving average of $305.01.

More news about argenx SE.

7. Albemarle (ALB) – 9.27%

Albemarle Corporation is a global manufacturer and marketer of engineered specialty chemicals. It operates three main segments, including Lithium and Bromine Specialties. Lithium offers lithium compounds such as lithium carbonate and lithium hydroxide as well as value-added specialties. There are also products made from cesium for pharmaceutical and chemical industries, zirconium and barium for various pyrotechnical purposes, as well as technical services such handling reactive lithium products and recycling of lithium-containing byproducts. Bromine specialties offers bromine and bromine solutions for chemical synthesis and mercury control. It also provides bromine-based products to water purification and beef processing. Catalysts offers hydroprocessing and isomerization catalysts, fluidized catalytic cracking and additives as well as performance catalyst solutions that include organometallics or curatives. It serves the following markets: energy storage, oil refining and consumer electronics; automotive; lubricants; pharmaceuticals; crop protection; custom chemistry service market. Albemarle Corporation was established in 1994. It is located in Charlotte, North Carolina.

NYSE ended the session with Albemarle jumping 9.27% to $235.44 on Thursday while NYSE slid 2.9% to $15,652.61.

Volume

Today's last reported volume for Albemarle is 3352980 which is 192.79% above its average volume of 1145160.

Albemarle's last close was $215.47, 26.08% below its 52-week high of $291.48.

Albemarle's Sales

Albemarle's sales growth is 2.2% for the ongoing quarter and a decline by 2.2% for the next. The company's growth estimates for the present quarter and the next is a negative 32.1% and a negative 23.9%, respectively.

Albemarle's Revenue

Year-on-year quarterly revenue growth grew by 12.2%, now sitting on 3.22B for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Albemarle's stock is considered to be oversold (<=20).

Albemarle's Stock Yearly Top and Bottom Value

Albemarle's stock is valued at $235.44 at 17:32 EST, way under its 52-week high of $291.48 and way higher than its 52-week low of $133.82.

Albemarle's Moving Average

Albemarle's value is under its 50-day moving average of $251.62 and way higher than its 200-day moving average of $199.35.

More news about Albemarle.

8. Compugen Ltd. (CGEN) – 8.7%

Compugen Ltd. is a company that specializes in clinical-stage therapeutic development and discovery. It also focuses on the development and commercialization therapeutic and product candidate candidates. Compugen Ltd.'s immuno-oncology portfolio includes COM701, an Anti-PVRIG antibody, which is currently in Phase 1 clinical trial and is used to treat solid tumors. BAY 1905254 is a Therapeutic antibody Targeting ILDR2, which has entered Phase 1 clinical trials in solid tumor patients. COM902, a Therapeutic antibody Targeting TIGIT. The company's therapeutic pipeline includes early-stage immunooncology programs that are primarily focused on myeloid targets. Bayer Pharma AG has a collaboration agreement for research, development and commercialization of antibody-based therapies against company's immune regulators. Bristol-Myers Squibb will evaluate the safety of COM701 with Opdivo, Bristol-Myers Squibb's PD-1 immuno checkpoint inhibitor Opdivo, in patients with advanced solid tumours. Johns Hopkins School of Medicine will evaluate new T cell and myeloid target areas. AstraZeneca has a license agreement for development of multi- and bi-specific immune-oncology antibodies products. Johns Hopkins University is collaborating in research on myeloid. Compugen Ltd. is an Israeli company that was founded in 1993. Its headquarters are in Holon.

NASDAQ ended the session with Compugen Ltd. jumping 8.7% to $2.50 on Thursday, following the last session's upward trend. NASDAQ dropped 4.99% to $12,317.69, after three sequential sessions in a row of gains, on what was a very bearish trend trading session today.

Volume

Today's last reported volume for Compugen Ltd. is 1115200 which is 25.1% above its average volume of 891395.

Compugen Ltd.'s last close was $2.50, 72.83% under its 52-week high of $9.20.

Compugen Ltd.'s Stock Yearly Top and Bottom Value

Compugen Ltd.'s stock is valued at $2.50 at 17:32 EST, way below its 52-week high of $9.20 and way above its 52-week low of $2.20.

Compugen Ltd.'s Moving Average

Compugen Ltd.'s value is way below its 50-day moving average of $2.93 and way under its 200-day moving average of $4.77.

More news about Compugen Ltd..

9. ClearSign Technologies Corporation (CLIR) – 8.46%

ClearSign Technologies Corporation develops and designs products and technologies that improve operational performance, efficiency, emission reduction and safety as well as overall cost effectiveness of commercial and industrial systems throughout the United States. ClearSign Core Burner Technology consists a industrial burner body with a porous ceramic structure downstream or metal flame stabilizing devices; ClearSign Core Plug & Play technology allows for direct replacement of traditional refinery heaters; ClearSign Clear Flame Sensor is an electric flame sensor that can be used in industrial applications; ClearSign also offers ClearSign core boiler burner and ClearSign core flaring burners technologies. The company serves the chemical, petrochemical, energy and commercial boiler industries. ClearSign Combustion Corporation was the company's former name. In November 2019, ClearSign Technologies Corporation took over. ClearSign Technologies Corporation was established in 2008. It is located in Seattle, Washington.

NASDAQ ended the session with ClearSign Technologies Corporation rising 8.46% to $1.41 on Thursday while NASDAQ fell 4.99% to $12,317.69.

Volume

Today's last reported volume for ClearSign Technologies Corporation is 27680 which is 61.41% below its average volume of 71745.

ClearSign Technologies Corporation's last close was $1.41, 73.79% below its 52-week high of $5.38.

ClearSign Technologies Corporation's Stock Yearly Top and Bottom Value

ClearSign Technologies Corporation's stock is valued at $1.41 at 17:32 EST, way below its 52-week high of $5.38 and way above its 52-week low of $1.00.

ClearSign Technologies Corporation's Moving Average

ClearSign Technologies Corporation's value is above its 50-day moving average of $1.39 and way under its 200-day moving average of $1.88.

More news about ClearSign Technologies Corporation.

10. Chembio Diagnostics (CEMI) – 8.41%

Chembio Diagnostics, Inc., along with its affiliates, creates, produces, and markets point-of care (POC), diagnostic tests used for diagnosing or diagnosing diseases. It offers testing for COVID-19 and HIV/Syphilis. The company also offers tests for malaria and dengue. It sells products under the STAT PAK, STURE CHECK and STAT VIEW trademarks. The private labels of marketing partners are also used to market its products to hospitals and medical labs. The company has agreements with The Bill & Melinda Gates Foundation and The Paul G. Allen Family Foundation and The Oswaldo Cruz Foundation. It also works closely with U.S. government agencies such as the Centers for Disease Control and Prevention and Biomedical Advanced and Research and Development Authority of U.S. Department of Health and Human Services and U.S. Department of Agriculture. Chembio Diagnostics, Inc., was established in 1985. It is located in Hauppauge, New York.

NASDAQ ended the session with Chembio Diagnostics jumping 8.41% to $0.62 on Thursday while NASDAQ dropped 4.99% to $12,317.69.

Volume

Today's last reported volume for Chembio Diagnostics is 82139 which is 72.83% below its average volume of 302410.

Chembio Diagnostics's last close was $0.62, 91.55% below its 52-week high of $7.34.

Chembio Diagnostics's Sales

Chembio Diagnostics's sales growth is 35.3% for the current quarter and 67.1% for the next. The company's growth estimates for the present quarter and the next is 4.5% and 57.8%, respectively.

Chembio Diagnostics's Revenue

Year-on-year quarterly revenue growth grew by 101.2%, now sitting on 47.82M for the twelve trailing months.

Chembio Diagnostics's Stock Yearly Top and Bottom Value

Chembio Diagnostics's stock is valued at $0.62 at 17:32 EST, way below its 52-week high of $7.34 and way higher than its 52-week low of $0.53.

Chembio Diagnostics's Moving Average

Chembio Diagnostics's worth is way below its 50-day moving average of $0.77 and way below its 200-day moving average of $1.75.

More news about Chembio Diagnostics.

Most Active Losers Today

1. China Auto Logistics (CALI) – -99%

China Auto Logistics Inc. and its subsidiaries sells and trades imported cars in the People's Republic of China. The company operates in three segments: Sales of Automobiles and Financing Services. It also provides financing services such as letter of credit, purchase deposit financing and services for import duties advances. Additionally, it offers automobile value-added service which includes assistance with customs clearance and storage as well as delivery and delivery. It also offers Web-based advertising through its websites, including at188.com which provides information about sales and trade for imported cars, parts, and components. At160.com provides real-time pricing and information on sales and trading. The company serves mainly authorized dealers, agents, wholesalers or free traders, as well as individual customers. Tianjin is the People's Republic of China's headquarters.

NASDAQ ended the session with China Auto Logistics falling 99% to $0.00 on Thursday while NASDAQ slid 4.99% to $12,317.69.

Volume

Today's last reported volume for China Auto Logistics is 1500 which is 149900% above its average volume of 1.

China Auto Logistics's last close was $0.00, 99.98% below its 52-week high of $0.48.

China Auto Logistics's Revenue

Year-on-year quarterly revenue growth grew by 30.1%, now sitting on 514.41M for the twelve trailing months.

China Auto Logistics's Moving Average

China Auto Logistics's worth is under its 50-day moving average of $0.00 and under its 200-day moving average of $0.03.

More news about China Auto Logistics.

2. Wayfair (W) – -25.82%

Wayfair Inc. is an e-commerce company that operates in the United States as well internationally. The company offers approximately 18 million home goods under different brands. It offers a variety of furniture and dA (c)cor products, as well as decorative accents and housewares. Wayfair Inc. was established in 2002. It is located in Boston, Massachusetts.

NYSE ended the session with Wayfair sliding 25.82% to $67.33 on Thursday while NYSE fell 2.9% to $15,652.61.

Volume

Today's last reported volume for Wayfair is 12410400 which is 376.09% above its average volume of 2606710.

Wayfair's last close was $114.45, 66.29% below its 52-week high of $339.56.

News about Wayfair today

• Wayfair swings to a loss, shares sink. According to today's article on MarketWatch, "Chief Executive Niraj Shah said in a statement that the Way Day event last week had "two of the four largest days in Wayfair's entire history." In a separate release, Wayfair named Kate Gulliver as chief financial officer, effective in November. "

Wayfair's Sales

Wayfair's sales growth is a negative 9.3% for the current quarter and a decline by 4.8% for the next. The company's growth estimates for the present quarter and the next is a negative 150.8% and a negative 143%, respectively.

Wayfair's Revenue

Year-on-year quarterly revenue growth declined by 18.7%, now sitting on 14.13B for the twelve trailing months.

Wayfair's Stock Yearly Top and Bottom Value

Wayfair's stock is valued at $67.33 at 17:33 EST, way under its 52-week low of $75.65.

Wayfair's Moving Average

Wayfair's value is way under its 50-day moving average of $114.05 and way under its 200-day moving average of $204.49.

More news about Wayfair.

3. Clovis Oncology (CLVS) – -20%

Clovis Oncology, Inc. is a biopharmaceutical firm that focuses on the acquisition, development, and marketing of anti-cancer drugs in the United States, Europe, and abroad. Rubraca, rucaparib, is an oral small molecule inhibitor poly ADPribose monomerase. It can be used to treat primary peritoneal, recurrent epithelial, and fallopian cancers, as well as metastatic castration resistant prostate cancer. The company also offers lucitanib (an investigational angiogenesis inhibitor), which inhibits the vascular endothelial grow factor receptors 1, 3 and 5 (VEGFR 1 and 3), as well as platelet-derivedgrowth factor receptors alpha, beta, and fibroblast growth factors receptors 1 and 3 (FGFR 1 and 3). FAP-2286 is a peptide targeted radionuclide treatment and imaging agent that targets fibroblast activation proteins. It distributes products through specialty pharmacies, distributors, and patients. Clovis Oncology, Inc. holds license agreements with Pfizer Inc., AstraZeneca UK Limited, Advenchen Laboratories LLC, Clovis Pharmaceuticals GmbH, 3B Pharmaceuticals GmbH, Bristol Myers Squibb Company, and 3B Pharmaceuticals GmbH; as well as a partnership agreement with Foundation Medicine, Inc. It was founded in 2009, and its headquarters are in Boulder, Colorado.

NASDAQ ended the session with Clovis Oncology falling 20% to $1.68 on Thursday, following the last session's downward trend. NASDAQ dropped 4.99% to $12,317.69, after three successive sessions in a row of gains, on what was a very bearish trend exchanging session today.

Volume

Today's last reported volume for Clovis Oncology is 12107800 which is 4.37% above its average volume of 11600000.

Clovis Oncology's last close was $1.68, 76.8% below its 52-week high of $7.24.

Clovis Oncology's Sales

Clovis Oncology's sales growth is a negative 7.5% for the current quarter and 17.4% for the next. The company's growth estimates for the present quarter and the next is 45.1% and 35.9%, respectively.

Clovis Oncology's Revenue

Year-on-year quarterly revenue growth declined by 2.2%, now sitting on 156.09M for the twelve trailing months.

Clovis Oncology's Stock Yearly Top and Bottom Value

Clovis Oncology's stock is valued at $1.68 at 17:33 EST, way under its 52-week high of $7.24 and way higher than its 52-week low of $1.35.

Clovis Oncology's Moving Average

Clovis Oncology's worth is way under its 50-day moving average of $1.97 and way under its 200-day moving average of $3.25.

More news about Clovis Oncology.

4. Fastly (FSLY) – -18.42%

NYSE ended the session with Fastly dropping 18.42% to $13.76 on Thursday while NYSE slid 2.9% to $15,652.61.

Volume

Today's last reported volume for Fastly is 9394740 which is 56.92% above its average volume of 5986610.

The company's growth estimates for the present quarter and the next is a negative 375% and a negative 77.8%, respectively.

More news about Fastly.

5. Etsy (ETSY) – -17.8%

NASDAQ ended the session with Etsy falling 17.8% to $89.87 on Thursday, after five successive sessions in a row of gains. NASDAQ dropped 4.99% to $12,317.69, after three consecutive sessions in a row of gains, on what was a very down trend trading session today.

Volume

Today's last reported volume for Etsy is 14082600 which is 242.63% above its average volume of 4110070.

Etsy's last close was $109.33, 64.47% under its 52-week high of $307.75.

Etsy's Sales

Etsy's sales growth is 11% for the present quarter and 20.3% for the next. The company's growth estimates for the current quarter and the next is a negative 29.6% and a negative 15%, respectively.

Etsy's Revenue

Year-on-year quarterly revenue growth grew by 16.2%, now sitting on 2.33B for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Etsy's stock is considered to be oversold (<=20).

Etsy's Stock Yearly Top and Bottom Value

Etsy's stock is valued at $89.87 at 17:33 EST, below its 52-week low of $92.86.

Etsy's Moving Average

Etsy's worth is way under its 50-day moving average of $128.01 and way below its 200-day moving average of $189.67.

More news about Etsy.

6. Nio (NIO) – -16.16%

NIO Limited manufactures and sells electric cars in China, Hong Kong and the United States. There are five, six and seven-seat electric SUVs available from the company. The company also provides energy and services packages for its customers; marketing, design and technology development activities; manufacturing of components and e-powertrains; as well as sales and after-sales management. The company also offers charging solutions such as Power Home, which is a home charging option; Power Swap (a battery swapping service); Power Mobile, which provides mobile charging services through charging trucks; Public Charger; a public fast-charging solution; and Power Express. This service allows for 24-hour pick-up-and-drop-off charging. It also offers value-added services such as third-party and statutory liability insurance and vehicle damage insurance through third party insurers, repair and routine maintenance, courtesy cars during long repairs, maintenance, roadside assistance and data packs. NIO Limited is a partner in the creation of autonomous and automated vehicles. It also has agreements of collaboration with other manufacturers to produce the ES8, a high-performance, six- or seven-seat electric SUV. NIO Limited was previously known as NextEV Inc. NIO Limited was established in 2014. It is located in Shanghai, China.

NYSE ended the session with Nio sliding 16.16% to $15.20 on Thursday while NYSE fell 2.9% to $15,652.61.

Volume

Today's last reported volume for Nio is 90480600 which is 27.66% above its average volume of 70874400.

Nio's last close was $16.07, 70.85% under its 52-week high of $55.13.

Nio's Sales

Nio's sales growth is 50.7% for the present quarter and 46.9% for the next. The company's growth estimates for the ongoing quarter is a negative 25% and positive 57.1% for the next.

Nio's Revenue

Year-on-year quarterly revenue growth grew by 116.6%, now sitting on 32.88B for the twelve trailing months.

Nio's Stock Yearly Top and Bottom Value

Nio's stock is valued at $15.20 at 17:33 EST, way under its 52-week high of $55.13 and way higher than its 52-week low of $13.01.

Nio's Moving Average

Nio's worth is way under its 50-day moving average of $19.84 and way under its 200-day moving average of $31.80.

More news about Nio.

7. Shopify (SHOP) – -15.33%

Shopify Inc. is a commerce company that offers a multi-channel cloud commerce platform to small and medium businesses across Canada, Australia, the United States and the United Kingdom. The platform gives merchants a single view into their business and customers across all sales channels. This includes Web and mobile storesfronts as well as physical locations and social media outlets. It also allows them to process orders and pay, ship and fulfill orders, manage inventory and products, create customer relationships and leverage analytics. Shopify Inc. was previously known as Jaded Pixel Technologies Inc. Shopify Inc. was established in 2004. It is located in Ottawa, Canada.

NYSE ended the session with Shopify sliding 15.33% to $411.07 on Thursday, after two sequential sessions in a row of losses. NYSE fell 2.9% to $15,652.61, after two successive sessions in a row of gains, on what was an all-around bearish trend exchanging session today.

Volume

Today's last reported volume for Shopify is 10961600 which is 237.88% above its average volume of 3244140.

Shopify's last close was $544.37, 69.12% under its 52-week high of $1,762.92.

News about Shopify today

• Shopify plunges after earnings miss, $2.1 billion startup deal. According to today's article on Bloomberg Quint, "In January, Shopify canceled several fulfillment and warehouse contracts intended to create its own distribution network.", "In a bid to draw retail investors, Shopify announced in April plans to split its stock 10-for-1."
• Shopify stock tumbles after earnings miss, announcement of $2.1 billion fulfillment acquisition. According to today's article on MarketWatch, "Our goal is to not only level the playing field for independent businesses, but tilt it in their favor – turning their size and agility into a superpower," Shopify Chief Executive Tobi Lütke said in a release. ", "Together with Deliverr, Shopify Fulfillment Network will give millions of growing businesses access to a simple, powerful logistics platform that will allow them to make their customers happy over and over again." Shares of Shopify have slid 45% over the past three months as the S&P 500 has lost about 4%."
• Shopify shares slump after earnings miss. According to today's article on MarketWatch, "Together with Deliverr, Shopify Fulfillment Network will give millions of growing businesses access to a simple, powerful logistics platform that will allow them to make their customers happy over and over again." Shares of Shopify have slid 45% over the past three months as the S&P 500 has lost about 4%.", "Shares of Shopify Inc. were sliding 15% in premarket trading Thursday after the e-commerce company fell short of expectations with its latest results and said it would spend $2.1 billion to acquire fulfillment-technology provider Deliverr. "
• Shopify earnings preview: welcome to the jungle, but is it time to buy SHOP stock?. According to today's article on FXStreet, "Amazon will be able to deploy huge amounts of capital to imitate any perceived improvements in the Shopify experience that retailers find likeable."

Shopify's Revenue

Year-on-year quarterly revenue growth grew by 46.4%, now sitting on 4.21B for the twelve trailing months.

Shopify's Stock Yearly Top and Bottom Value

Shopify's stock is valued at $411.07 at 17:33 EST, under its 52-week low of $411.17.

Shopify's Moving Average

Shopify's value is way below its 50-day moving average of $612.76 and way below its 200-day moving average of $1,183.56.

More news about Shopify.

8. Cloudflare (NET) – -14.67%

NYSE ended the session with Cloudflare falling 14.67% to $77.14 on Thursday, after four successive sessions in a row of losses. NYSE slid 2.9% to $15,652.61, after two sequential sessions in a row of gains, on what was an all-around bearish trend exchanging session today.

Volume

Today's last reported volume for Cloudflare is 8014680 which is 53.62% above its average volume of 5216990.

Cloudflare's Sales

Cloudflare's sales growth is 60.6% for the present quarter and 39.6% for the next. The company's growth estimates for the ongoing quarter and the next is a negative 100% and a negative 50%, respectively.

Cloudflare's Revenue

Year-on-year quarterly revenue growth grew by 52.9%, now sitting on 530.57M for the twelve trailing months.

More news about Cloudflare.

9. Freshpet (FRPT) – -14.66%

Freshpet, Inc. produces and markets fresh, natural products, frozen meals, treats, and other pet care items in the United States, Canada, the United Kingdom, and internationally. It sells products under its Freshpet and Dognation brands. The brand is also available online. Freshpet, Inc., was established in Secaucus, New Jersey in 2004.

NASDAQ ended the session with Freshpet dropping 14.66% to $68.80 on Thursday, after five consecutive sessions in a row of losses. NASDAQ fell 4.99% to $12,317.69, after three consecutive sessions in a row of gains, on what was a very down trend trading session today.

Volume

Today's last reported volume for Freshpet is 1992670 which is 247.34% above its average volume of 573686.

Freshpet's last close was $80.62, 56.88% below its 52-week high of $186.98.

Freshpet's Sales

Freshpet's sales growth is 44.6% for the current quarter and 36.7% for the next. The company's growth estimates for the present quarter is a negative 25% and positive 19.2% for the next.

Freshpet's Revenue

Year-on-year quarterly revenue growth grew by 27.8%, now sitting on 394.14M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Freshpet's stock is considered to be overbought (>=80).

Freshpet's Stock Yearly Top and Bottom Value

Freshpet's stock is valued at $68.80 at 17:33 EST, way under its 52-week low of $78.81.

Freshpet's Moving Average

Freshpet's value is way under its 50-day moving average of $100.38 and way under its 200-day moving average of $117.21.

More news about Freshpet.

10. MicroStrategy (MSTR) – -14.27%

MicroStrategy Incorporated offers enterprise analytics software and other services around the world. MicroStrategy 2020 is an enterprise platform that provides analytics across multiple devices. It allows analysts and data scientists seamless access to trust-governed data within their tool. MicroStrategy support is available to customers in order to help them achieve system availability, uptime and improve their overall user experience. This includes proactive product support and highly responsive technical troubleshooting. It also offers MicroStrategy Consulting, which provides architecture and implementation services that help customers quickly achieve results and maximize returns on their investment. It provides services via channel partners and enterprise sales. The company serves customers from many industries including technology, retail, consulting and manufacturing. It also provides services through channel partners. It was established in Tysons Corner in Virginia in 1989.

NASDAQ ended the session with MicroStrategy dropping 14.27% to $314.16 on Thursday while NASDAQ slid 4.99% to $12,317.69.

Volume

Today's last reported volume for MicroStrategy is 778198 which is 84.19% above its average volume of 422485.

MicroStrategy's last close was $366.44, 58.89% under its 52-week high of $891.38.

MicroStrategy's Sales

MicroStrategy's sales growth is 1.4% for the ongoing quarter and 15% for the next. The company's growth estimates for the ongoing quarter is 292.3% and a drop 11% for the next.

MicroStrategy's Revenue

Year-on-year quarterly revenue growth grew by 0.5%, now sitting on 507.57M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

MicroStrategy's stock is considered to be oversold (<=20).

MicroStrategy's Stock Yearly Top and Bottom Value

MicroStrategy's stock is valued at $314.16 at 17:33 EST, way under its 52-week high of $891.38 and above its 52-week low of $307.19.

MicroStrategy's Moving Average

MicroStrategy's worth is way under its 50-day moving average of $436.19 and way under its 200-day moving average of $572.99.

Previous days news about MicroStrategy

• Microstrategy quarterly loss widens on Bitcoin impairment charge. According to Bloomberg Quint on Tuesday, 3 May, "Shares of Tysons Corner, Virginia-based MicroStrategy fell 2.2% in post-market trading. ", "That's the lowest quarterly revenue since MicroStrategy started its Bitcoin investment strategy in August 2020. "

More news about MicroStrategy.

Stay up to date with our winners and losers daily report